期刊文献+

丁酸钠增强5-aza-dC对人胃癌MKN-28细胞生长的抑制作用 被引量:1

Sodium butyrate enhances the inhibitory effect of 5-aza-2'-deoxycytidine on the growth of human gastric cancer MKN-28 cell lines
原文传递
导出
摘要 目的探讨丁酸钠(NaB)和5-氮-2′-脱氧胞苷(5-aza-dC)对胃癌细胞MKN-28细胞生长抑制的协同作用。方法 MKN-28细胞分为5-aza-dC组(A组)、NaB组(B组)、5-aza-dC+NaB组(C组)和对照组(D组)。四甲基偶氮唑盐比色(MTT)法观察人胃癌MKN-28细胞生长,流式细胞术检测细胞周期及细胞凋亡。结果 C组对MKN-28细胞的生长抑制作用明显强于A、B组(P<0.05);A组对细胞周期无影响,而B组及C组均可使细胞周期阻滞于G0/G1期(P<0.05);C组诱导的细胞凋亡率明显高于A、B组[(33.7±3.1)%vs.(8.3±1.3)%、(20.8±2.4)%](P<0.05)。结论 NaB可增强5-aza-dC对人胃癌MKN-28细胞的生长抑制作用,此协同作用可能与阻滞细胞周期及诱导细胞凋亡有关。 Objective To examine the synergic inhibitory effect of sodium butyrate(NaB) and demethylating agent 5-aza-2'-deoxycytidine(5-aza-dC) on the cell growth of human gastric cancer cell line MKN-28.Methods The MKN-28 cells were divided into 4 groups of A(treated with NaB),B(treated with 5-aza-dC),C(treated with NaB plus 5-aza-dC) and D(without treatment as the control).MTT assay was used to observe the cell cycle of cell growth and flow cytometry was used for analyzing the cell apoptosis.Results Compared with 5-aza-2'-deoxycytidine or sodium butyrate alone,the inhibitory effect on the cell growth was higher in group C than that in groups of A and B(P〈0.05).No significant change in cell cycle was seen in group A.The sell ratio of G0/G1 phase was significantly increased in groups of B and C(P〈0.05).The cell apoptosis rate was higher in group C than that in groups of A and B[(33.7±3.1)% vs.(8.3±1.3)% and (20.8±2.4)%](P〈0.05).Conclusion Sodium butyrate enhances the inhibitory effect of 5-aza-2'-deoxycytidine on the growth of human gastric cancer MKN-28 cell lines,which may be related to inducing apoptosis and arresting cell cycles.
出处 《江苏医药》 CAS CSCD 北大核心 2010年第12期1410-1413,共4页 Jiangsu Medical Journal
基金 江苏省医学重点人才基金(RC2007076)
关键词 5-氮-2′-脱氧胞苷 丁酸钠 胃癌 5-aza-2'-Deoxycytidine Sodium butyrate Gastric cancer
  • 相关文献

参考文献11

  • 1Kikuehi T, Itoh F, Toyota M, et al. Aberrant methylation and histone daacetylation of cyclooxygenase 2 in gastric cancer [J]. Int J Cancer,2002,97(3) ;272-277.
  • 2高楠,陈卫昌,岑建农.人胃癌组织中Runx3、Dnmt1表达及其临床意义[J].江苏医药,2008,34(3):230-232. 被引量:1
  • 3Brow NR,Plumb JA. Demethylation of DNA by decitabine in cancer chemotherapy[J]. Expert Rev Anticancer Ther, 2004, 4(4) : 501-510.
  • 4Esteller M. Relevance of DNA methylation in the management of cancer[J]. Lancet Chacol, 2003,4 (6) : 351-358.
  • 5Lyko F, Brown R. DNA methyltransferences inhibitors and the development of epigenetic cancer therapies[J]. J Natl Cancer Inst, 2005,97 (20) : 1498-1506.
  • 6Yang Q, Shan L, Yoshimura G, et al. 5-aza-2'-deoxycytidine induces retinoic acid receptor beta 2 demethylation, cell cycle arrest and growth inhibition in breast carcinomacells[J]. Anticancer Res, 2002,22 (5) : 2753 -2756.
  • 7Fang JY. Histone deacetylase inhibitors-antieancerous mechanism and therapy for gastrointestinal cancers[J]. J Gastroenterol Hepatol, 2005,20(7) : 988- 994.
  • 8Wilson A J, Byun DS, Popova N, et al. Histone deaeetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer[J]. Biol Chem, 2006,281 (19) : 13548-13558.
  • 9Amita P,Eric KR,Miguel AA. Phase Ⅰ study of pivaloyloxymethyl butyrate,a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies[J]. Clin Cancer Res, 2002,8(7) : 2142-2148.
  • 10Drummoud DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents [J]. Annu Rev Pharmacol Toxicol, 2005,45 (1) : 495-528.

二级参考文献11

  • 1Mori T, Nomoto S, Koshikawa K, et al. Decreased expression and frequent allelic inactivation of the RUNX3 gene at lp36 in human hepatocellar carcinoma [J]. Liver Int, 2005,25 (2) :380-388.
  • 2Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer [J]. Cell,2002,109(1) : 113-124.
  • 3Issa JP, Vertino PM, Wu J, et al. Increased cytosine DNA methyltransferase activity during colon cancer progression [J]. J Natl Cancer Inst, 1993,85(15) : 1235-1240.
  • 4Li J, Kleeff J, Guweidhi A, et al. RUNX3 expression in primary and metastatic pancreatic cancer [J]. J Clin Pathol, 2004,57 (3) : 294-299.
  • 5Vogiatzi P, Defalco G, Claudio P, et al. How does the human RUNX3 gene induce apoptosis in gastric cancer? Latest data, reflections and reaction [J]. Cancer Biol Ther, 2006, 5(4) :371-376.
  • 6Sakakural C, Hagiwara A, Miyagawa K, et al. Frequent downregulation of the runt domain transcription factors RUNX1, RUNX3 and their cofactor CBFB in gastric cancer [J]. Int J Cancer, 2005,113(2):221-228.
  • 7Brown KD, Robertson KD. DNMT1 knockout delivers a strong blow to genome stability and cell viability [J]. Nat Genet,2007, 39(3) :289-290.
  • 8Brueckner B, Kuck D, Lyko F. DNA methyltransferase inhibitors for cancer therapy [J]. Cancer Journal, 2007, 13 (1): 17-22.
  • 9Shieh YS, Shieh SG, Jeng HH, et al. DNA methyltransferse 1 expression and promoter methylation of E-cadherin in mucoepidermoid carcinoma [J]. Cancer, 2005, 104 (5) : 1013- 1021.
  • 10Kanai Y, Ushijima S, Kondo Y, et al. DNA methyltransferase expression and DNA methylation of CpG islands and peri-centromeric satellite regions in human colorectal and stomach cancers [J]. Int J Cancer, 2001,91 (2) : 205-212.

同被引文献29

  • 1李晓晖,李建勋,李世荣,修志龙,西野宪和.环肽类组蛋白去乙酰化酶抑制剂[J].化学进展,2007,19(5):762-768. 被引量:7
  • 2张波,陈剑英,王国斌,陈道达.组蛋白去乙酰酶抑制剂对结肠癌细胞增殖和ID4基因表达的影响[J].世界华人消化杂志,2007,15(18):2021-2025. 被引量:3
  • 3Johnstone RW. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1(4): 287- 99.
  • 4Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265(28): 17174-9.
  • 5Kim H J, Bae SC. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011; 3(2): 166-79.
  • 6Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109(1): 31-9.
  • 7Piekarz RL, Frye R, Turner M, Wright J J, Allen SL, Kirschbaum MH, et al. Phase II multi-institutional trial of the histone deacety- lase inhibitor romidepsin as monotherapy for patients with cuta- neous T-cell lymphoma. J Clin Oncol 2009; 27(32): 5410-7.
  • 8Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, Ueno K, et al. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer 2011; 128(8): 1793-803.
  • 9Belinsky SA, Grimes M J, Picchi MA, Mitchell HD, Stidley CA, Tesfaigzi Y, et al. Combination therapy with vidaza and entinos- tat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res 2011; 71 (2): 454-62.
  • 10Xu Q, Lu R, Zhu ZF, Lv JQ, Wang L J, Zhang W, et al. Effects of tyroservatide on histone acetylation in lung carcinoma cells, Int J Cancer 2011; 128(2): 460-72.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部